Comparison of the Effect of Empagliflozin and Glimepiride on the Endothelial Function in Patients with Type 2 Diabetes—A Randomized Study

Reportedly, patients with type 2 diabetes at a high risk for cardiovascular events receiving empagliflozin, compared with placebo, have a lower rate of the primary composite cardiovascular outcome and death from any cause. This study compares the effect of empagliflozin and glimepiride on the endothelial function in patients with type 2 diabetes by flow-mediated dilation (FMD). This prospective, randomized, parallel-group comparison study...